Key facts
- This page summarizes Janet S. Vergis's Form 4 filing for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA).
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 Jun 2025, 16:25.
Janet S. Vergis - 05 Jun 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)
- Reporting relationship
- Director
- Issuer ticker
- TEVA
- Reported as of
- 05 Jun 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2025, 16:25:12 UTC
- Prior SEC filing
- 27 May 2025
- Next SEC filing
- 08 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Dov Bergwerk as attorney-in-fact for Janet S. Vergis
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Janet S. Vergis filed Form 4 for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) on 09 Jun 2025.
Change
- Previous filing in this sequence was filed on 27 May 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001590794
Primary reporting owner
Vergis Janet S.
- Relationship
- Director
- Address
- C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL
- Signature
- /s/ Dov Bergwerk as attorney-in-fact for Janet S. Vergis
- Signature date
- 09 Jun 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
TEVA
transaction
Ordinary Shares
Options Exercise
- Transaction value
- Shares
- +9,632
- Change %
- +15%
- Price
- Shares after
- 73,697
- Date
- 06 Jun 2025
- Ownership
- Direct
- Footnotes
- F1, F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
TEVA
transaction
Derivative
Restricted Share Units
Options Exercise
- Transaction value
- $0
- Shares
- -9,632
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 06 Jun 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 9,632
- Exercise price
- Footnotes
- F1, F2, F3
TEVA
transaction
Derivative
Restricted Share Units
Award
- Transaction value
- $0
- Shares
- +14,492
- Change %
- Price
- $0.000000
- Shares after
- 14,492
- Date
- 05 Jun 2025
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 14,492
- Exercise price
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Footnote F2
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Footnote F3
Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
Footnote F4
Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.